Chinese Journal of Antituberculosis ›› 2018, Vol. 40 ›› Issue (8): 815-820.doi: 10.3969/j.issn.1000-6621.2018.08.008
• Original Articles • Previous Articles Next Articles
Fei REN,You XU,Li-yun DANG(),Yan-qin WU,Jin-bao MA,Si-si. ZHENG
Received:
2018-04-22
Online:
2018-08-10
Published:
2018-09-09
Contact:
Li-yun DANG
E-mail:xaxkyyny@163.com
Fei REN,You XU,Li-yun DANG,Yan-qin WU,Jin-bao MA,Si-si. ZHENG. Observation and comparative analysis on the adverse drug reactions of amikacin and capreomycin in treating multidrug resistant tuberculosis patients[J]. Chinese Journal of Antituberculosis, 2018, 40(8): 815-820. doi: 10.3969/j.issn.1000-6621.2018.08.008
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2018.08.008
[1] | World Health Organization . Global tuberculosis report 2017. Geneva: World Health Organization, 2017. |
[2] | 孔雯, 刘巧, 陆伟 , 等. 标准化耐多药肺结核化疗方案的不良反应及治疗转归情况分析. 中华疾病控制杂志, 2014,18(7):610-612. |
[3] |
中国防痨协会. 耐药结核病化学治疗指南(2015年). 中国防痨杂志, 2015,37(5):421-469.
doi: 10.3969/j.issn.1000-6621.2015.05.001 URL |
[4] |
World Health Organization . WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update. Geneva: World Health Organization, 2016.
URL pmid: 27748093 |
[5] |
高孟秋, 宋艳华 . 注射用抗结核药物在结核病治疗中的应用. 中华结核和呼吸杂志, 2014,37(10):149-151.
doi: 10.3760/cma.j.issn.1001-0939.2014.10.005 URL |
[6] |
Reuter A, Tisile P, von Deflt D, et al. The devil we know:is the use of injectable agents for the treatment of MDR-TB justified? Int J Tuberc Lung Dis, 2017,21(11):1114-1126.
doi: 10.5588/ijtld.17.0468 URL pmid: 29037291 |
[7] | 中华医学会. 临床诊疗指南:结核病分册.北京: 人民卫生出版社, 2005: 86. |
[8] |
谭守勇, 黎燕琼 . 加强耐多药结核病患者的药物不良反应管理. 结核病与肺部健康杂志, 2015,4(4):213-214.
doi: 10.3969/j.issn.2095-3755.2015.04.001 URL |
[9] | 肖桂荣, 吴逢波, 龙霞 , 等. 抗结核药物不良反应管理的国内外指南综述分析. 药物流行病学杂志, 2014,23(7):444-449. |
[10] | 田勇泉 .耳鼻咽喉头颈外科学.8版.北京: 人民卫生出版社, 2017: 305-307. |
[11] | 唐神结, 高文 .临床结核病学.北京: 人民卫生出版社, 2011: 191-200. |
[12] |
张红伟, 高志东, 贺晓新 , 等. 个体化方案治疗耐多药肺结核患者不良反应分析. 中国防痨杂志, 2016,38(2):133-138.
doi: 10.3969/j.issn.1000-6621.2016.02.012 URL |
[13] | 李佺, 陆兰英, 王娅 , 等. 335例耐多药结核病患者药物不良反应临床分析. 中国热带医学, 2017,17(7):725-727. |
[14] |
Ribeiro L, Sousa C, Sousa A , et al. Evaluation of hearing in patients with multi-resistant tuberculosis. Acta Med Port, 2015,28(1):87-91.
doi: 10.20344/amp.5783 URL |
[15] | Arnold A, Cooke GS, Kon OM , et al.Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2017, 61(9) pii:e02586-16. |
[16] |
Vasconcelos KA, Frota SMMC, Ruffino-Netto A , et al. The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis. Rev Soc Bras Med Trop, 2017,50(5):646-651.
doi: 10.1590/0037-8682-0465-2016 URL |
[17] | 刘博 . 加强耳鸣规范化综合治疗的研究和发展. 中华耳科学杂志, 2016,14(2):137-139. |
[18] |
Garcia-Prats AJ, Schaaf HS, Hesseling AC . The safety and to-lerability of the second-line injectable antituberculosis drugs in children. Expert Opin Drug Saf, 2016,15(11):1491-1500.
doi: 10.1080/14740338.2016.1223623 URL pmid: 27548570 |
[19] |
Meressa D, Hurtado RM, Andrews JR , et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study. Thorax, 2015,70(12):1181-1188.
doi: 10.1136/thoraxjnl-2015-207374 URL |
[20] |
Varma T, Saini A, Panchani R , et al. Two unusual cases of severe recalcitrant hypocalcemia due to aminoglycoside-induced hypomagnesemia. Indian J Endocrinol Metab, 2013,17(1):S206-S208.
doi: 10.4103/2230-8210.119573 URL |
[21] |
Modongo C, Sobota RS, Kesenogile B , et al. Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss. BMC Infect Dis, 2014,14:542.
doi: 10.1186/1471-2334-14-542 URL |
[22] | van Altera R, Dijkstra JA, van der Meer ME , et al. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.Antimicrob Agents Chemother, 2017, 61(3) pii:e01400-1416. |
[23] | 赵螈, 雷倩, 党丽云 , 等. 抗结核药物血药浓度监测工作的思考和展望. 中国防痨杂志, 2017,39(11):1228-1232. |
[1] | LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008. |
[2] | Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893. |
[3] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[4] | ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[8] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[9] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[10] | LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941. |
[11] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[12] | DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955. |
[13] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[14] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[15] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||